logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 11352316 B1

PDFFull Text
Date of Patent:
Jun. 07, 2022

Filed:

Jul. 10, 2020

Opioid receptor modulators and products and methods related thereto

Applicant:

Epiodyne, Inc., San Francisco, CA (US);

Inventors:

Julio Cesar Medina, South San Francisco, CA (US);

Lawrence R McGee, South San Francisco, CA (US);

Zhi-Liang Wei, South San Francisco, CA (US);

Corinne Sadlowski, South San Francisco, CA (US);

Frederick Seidl, South San Francisco, CA (US);

Ulhas Bhatt, South San Francisco, CA (US);

Xiaodong Wang, South San Francisco, CA (US);

Thomas Nguyen, South San Francisco, CA (US);

David Sperandio, South San Francisco, CA (US);

Pingyu Ding, South San Francisco, CA (US);

Alok Nerurkar, South San Francisco, CA (US);

Yihong Li, South San Francisco, CA (US);

Jason Duquette, Union City, CA (US);

Assignee:

EPIODYNE, INC., San Francisco, CA (US);

Attorney:

Wilson Sonsini Goodrich & Rosati

Primary Examiner:

Golam M Shameem

Int. Cl.
CPC ...
C07C 233/78 (2006.01); A61P 23/00 (2006.01); C07C 233/62 (2006.01); C07C 233/63 (2006.01); C07C 235/60 (2006.01); C07C 237/42 (2006.01); C07D 207/16 (2006.01); C07D 209/14 (2006.01); C07D 217/06 (2006.01); C07D 217/14 (2006.01); C07D 231/56 (2006.01); C07D 241/24 (2006.01); C07D 263/58 (2006.01); C07D 295/13 (2006.01); C07D 403/06 (2006.01); C07D 471/04 (2006.01); C07C 237/30 (2006.01); C07C 237/38 (2006.01); C07C 237/48 (2006.01); C07C 271/20 (2006.01); C07C 275/24 (2006.01); C07D 209/34 (2006.01); C07D 213/40 (2006.01); C07D 401/12 (2006.01);
U.S. Cl.
CPC ...
C07C 233/78 (2013.01); A61P 23/00 (2018.01); C07C 233/62 (2013.01); C07C 233/63 (2013.01); C07C 235/60 (2013.01); C07C 237/30 (2013.01); C07C 237/38 (2013.01); C07C 237/42 (2013.01); C07C 237/48 (2013.01); C07C 271/20 (2013.01); C07C 275/24 (2013.01); C07D 207/16 (2013.01); C07D 209/14 (2013.01); C07D 209/34 (2013.01); C07D 213/40 (2013.01); C07D 217/06 (2013.01); C07D 217/14 (2013.01); C07D 231/56 (2013.01); C07D 241/24 (2013.01); C07D 263/58 (2013.01); C07D 295/13 (2013.01); C07D 401/12 (2013.01); C07D 403/06 (2013.01); C07D 471/04 (2013.01);
Abstract

Compounds are provided having the structure of Formula (I): or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope, or salt thereof, wherein A, B, L, R, R, R, R, R, m and n are as defined herein. Such compounds modulate the opioid receptor, particulare the mu-opioid receptor (MOR) and/or the kappa-opioid receptor (KOR), and/or the delta-opioid receptor (DOR). Products containing such compounds, as well as methods for their use and preparation, are also provided.

Find Patent Forward Citations

Loading…